# About Advantage Peptides — An Independent Recovery Research Desk

> About Advantage Peptides: an independent literature digest on Recovery & Tissue Repair research peptides. How it is compiled, what it covers, and what it is not — not a seller, not a clinic, not medical advice.

An independent, citation-anchored digest of the recovery-and-repair peptide literature. Not a vendor. Not a clinic. Not medical advice.

## What Advantage Peptides is

Advantage Peptides is an independent editorial reference desk covering the published and mechanistic research on three peptides studied for tissue repair, tendon and ligament healing, gut mucosa, wound healing and angiogenesis: BPC-157, GLOW, and KLOW, with BPC-157 as the lead compound. The desk's organizing idea is **the recovery edge** — the point where active researchers are extending a single well-characterized mechanism (angiogenic, tissue-protective signaling) outward into progressively more complex, and progressively less directly tested, multi-peptide combinations.

BPC-157 has the most — if still very limited — human data of the three: a formal pharmacokinetic study, several rodent efficacy studies, and a small handful of human pilot reports. GLOW and KLOW are unstandardized research combinations that have never been tested as combinations; everything said about them is drawn from research into their individual components. This desk treats that distinction as the whole point, not a footnote — it says plainly which claims rest on a study of the compound in question, and which rest on an extrapolation.

## How it is compiled

Two principles govern what appears on this site. First, every research claim is anchored to a specific, citable source — peer-reviewed journal articles, PubMed-indexed reviews, and pharmacology studies, collected in full on the [references page](/references). Findings from animal models are described as animal findings; findings from narrow human pilot studies are described with their actual sample size; and findings that are purely mechanistic reasoning, rather than a tested outcome, are labeled as such.

Second, community-reported experience is kept clearly separate from clinical evidence. Where this desk describes what people in research-use communities say about BPC-157, GLOW, or KLOW, that material is explicitly and repeatedly labeled anecdotal, not clinical evidence, and it never carries a dose. The two categories — cited research and anecdotal report — are never blended into one undifferentiated claim.

## What it is not

Advantage Peptides is not a pharmacy, a clinic, a telehealth platform, or a vendor of any kind. It does not sell, supply, source, or broker any peptide, and it has no affiliate or referral relationship with any research-chemical supplier. It does not employ clinicians, diagnose conditions, or prescribe anything, and it does not recommend a dose, schedule, or route of administration for any person.

None of the three compounds covered here is an FDA-approved medicine. All are sold by research suppliers for laboratory research use, not human consumption. Readers with a clinical question about tissue repair, tendon or ligament healing, or any of the compounds discussed here should consult a licensed healthcare provider. Editorial correspondence on citation corrections or newly published research can be directed to the [contact page](/contact); this desk cannot respond to requests for medical advice.

---

Advantage Peptides is a calm, citation-anchored reference desk for tissue-repair research peptides — not a clinic, not a supplier, and not a source of medical advice.